Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
ZUAFu9TGjxdDb5SJ
